Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer
Not Applicable
- Conditions
- unresectable locally advanced pancreatic cancer
- Registration Number
- JPRN-UMIN000020475
- Lead Sponsor
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
(1)other distant metastasis (2)allergy of gemcitabine or nab-paclitaxel (3)invasion of digestive tract (4)severe drug allergy (5)active infection (6)severe heart disease (7)severe complications(bowel obstruction, lung fibrosis, interstitial pneumonia, diabetes, renal failure, liver cirrhosis) (8)active synchronous cancer (9)peripheral neuropathy (10)uncontrollable ascites or pleural effusion (11)active gastrointestinal bleeding (12)severe diarrhea (13)mental disorder (14)pregnancy (15)no informed consent (16)inappropriate case (17)pulmonary fibrosis, interstitial pneumonia (18)history of abdominal irradiation (19)uncontrollable carcinomatous pain (20)Lung in the pulmonary field
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method incidence of dose limiting toxicity (within 2 courses)
- Secondary Outcome Measures
Name Time Method